GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sensei Biotherapeutics Inc (NAS:SNSE) » Definitions » EV-to-EBIT

Sensei Biotherapeutics (Sensei Biotherapeutics) EV-to-EBIT : 0.59 (As of May. 15, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Sensei Biotherapeutics EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Sensei Biotherapeutics's Enterprise Value is $-20.17 Mil. Sensei Biotherapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-33.96 Mil. Therefore, Sensei Biotherapeutics's EV-to-EBIT for today is 0.59.

The historical rank and industry rank for Sensei Biotherapeutics's EV-to-EBIT or its related term are showing as below:

SNSE' s EV-to-EBIT Range Over the Past 10 Years
Min: 0   Med: 0   Max: 2.82
Current: 0.59

During the past 6 years, the highest EV-to-EBIT of Sensei Biotherapeutics was 2.82. The lowest was 0.00. And the median was 0.00.

SNSE's EV-to-EBIT is ranked better than
75.41% of 427 companies
in the Biotechnology industry
Industry Median: 10.05 vs SNSE: 0.59

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Sensei Biotherapeutics's Enterprise Value for the quarter that ended in Dec. 2023 was $-42.23 Mil. Sensei Biotherapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-33.96 Mil. Sensei Biotherapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 80.41%.


Sensei Biotherapeutics EV-to-EBIT Historical Data

The historical data trend for Sensei Biotherapeutics's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sensei Biotherapeutics EV-to-EBIT Chart

Sensei Biotherapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial - - -0.89 1.10 1.24

Sensei Biotherapeutics Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.10 0.89 0.91 1.16 1.24

Competitive Comparison of Sensei Biotherapeutics's EV-to-EBIT

For the Biotechnology subindustry, Sensei Biotherapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sensei Biotherapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sensei Biotherapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Sensei Biotherapeutics's EV-to-EBIT falls into.



Sensei Biotherapeutics EV-to-EBIT Calculation

Sensei Biotherapeutics's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=-20.172/-33.957
=0.59

Sensei Biotherapeutics's current Enterprise Value is $-20.17 Mil.
Sensei Biotherapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-33.96 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sensei Biotherapeutics  (NAS:SNSE) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Sensei Biotherapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=-33.957/-42.2281016
=80.41 %

Sensei Biotherapeutics's Enterprise Value for the quarter that ended in Dec. 2023 was $-42.23 Mil.
Sensei Biotherapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-33.96 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sensei Biotherapeutics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Sensei Biotherapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Sensei Biotherapeutics (Sensei Biotherapeutics) Business Description

Traded in Other Exchanges
Address
1405 Research Boulevard, Suite 710, Boston, MA, USA, 02210
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. The company currently has three investigational products. 1) SNS-101 is a conditionally active monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T-cell activation): 2) SNS-102 is a conditionally active monoclonal antibody targeting VSIG4 (V-Set and Immunoglobulin Domain Containing 4), an immune checkpoint often expressed on macrophages: 3) SNS-103 is a conditionally active monoclonal antibody targeting ENTPDase1 (ecto-nucleoside triphosphate diphosphohydrolase-1), also known as CD39.
Executives
Stephanie Krebs officer: Chief Business Officer C/O SENSEI BIOTHERAPEUTICS, INC., 1405 RESEARCH BLVD, SUITE 125, ROCKVILLE MD 20850
John Celebi director, officer: President & CEO SENSEI BIOTHERAPEUTICS, INC., 1405 RESEARCH BLVD., STE. 125, ROCKVILLE MD 20850
James Peyer director, 10 percent owner C/O SENSEI BIOTHERAPEUTICS, INC., 1405 RESEARCH BLVD., STE. 125, ROCKVILLE MD 20850
Cambrian Biopharma Inc 10 percent owner, other: See Remarks 228 PARK AVENUE S., #66643, NEW YORK NY 10003
Apeiron Investment Group Ltd. 10 percent owner BLOCK A, APT.12, IL-PIAZZETTA, TOWER ROAD, SLIEMA O1 SLM1605
Presight Sensei Co-invest Fund, L.p. other: See Explanation of Responses 340 S. LEMON AVE., # 3391, WALNUT CA 91789
Van Der Horst Edward officer: Chief Scientific Officer C/O SENSEI BIOTHERAPEUTICS, INC., 451 D STREET, SUITE 710, BOSTON MA 02210
Presight Co-invest Management, L.l.c. 10 percent owner 340 SOUTH LEMON AVENUE #3391, WALNUT CA 91789
Christian Angermayer 10 percent owner BLOCK A, APT.12, IL-PIAZZETTA, TOWER ROAD, SLIEMA O1 SLM1605
Patrick Stephen Gallagher officer: Chief Business Officer 66 HAROLD ST, BOSTON MA 02119
William R Ringo director
Thomas G Ricks director H&S VENTURES LLC, 2101 EAST COAST HWY - 3RD FLOOR, CORONA DEL MAR CA 92625
Robert Hamilton Pierce officer: Chief Scientific Officer C/O SENSEI BIOTHERAPEUTICS, INC., 1405 RESEARCH DR.., STE. 125, ROCKVILLE MD 20850
Kristian Humer director C/O VIRIDIAN THERAPEUTICS, INC., 6200 LOOKOUT ROAD, BOULDER CO 80301
Jessie English director C/O SENSEI BIOTHERAPEUTICS, INC., 1405 RESEARCH DR., STE. 125, ROCKVILLE MD 20850

Sensei Biotherapeutics (Sensei Biotherapeutics) Headlines

From GuruFocus